RENE.L Regulatory News (RENE)

15 Jun 2007 07:01

ReNeuron Group plc15 June 2007 Millipore Corporation to promote ReNeuron's ReNcell(R) neural stem cell lines atleading international stem cell conference Guildford, UK, 15 June 2007: ReNeuron Group plc (LSE: RENE.L) today announcesthat US-based Millipore Corporation, the exclusive distributor of ReNeuron'sReNcell(R)CX and ReNcell(R)VM neural cell lines, will highlight characteristicsof the cell lines in a presentation to be given by Dr Vi Chu, MilliporeBioscience Division, at the 5th International Society for Stem Cell Research(ISSCR) Annual Meeting in Cairns, Australia on 17-20 June. The presentation isscheduled for 08:00 am local time on 20 June. The ReNcell(R) neural cell lines are being marketed through MilliporeCorporation's reagent catalogue as drug discovery tools for academic andcommercial research. ReNeuron recently announced the publication of datadescribing the characteristics of these cell lines in the on-line journal BMCNeuroscience, generated in collaboration with the Department of Physiology,University College London. Further information relating to the ISSCR meeting may be found at www.isscr.org/meetings. Enquiries: ReNeuronMichael Hunt, Chief Executive Officer Tel: +44 (0) 1483 302560Dr John Sinden, Chief Scientific Officer Financial DynamicsDavid Yates Tel: +44 (0) 20 7831 3113Nicola Daley About ReNeuron ReNeuron is a leading, UK-based stem cell therapy business. It is applying itsnovel stem cell platform technologies in the development of ground-breaking stemcell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron has used its c-mycER technology to generate genetically stable neuralstem cell lines. This technology platform has multi-national patent protectionand is fully regulated by means of a chemically-induced safety switch. Cellgrowth can therefore be completely arrested prior to in vivo implantation. ReNeuron has filed for approval to commence initial clinical studies in the USwith its lead ReN001 stem cell therapy for chronic stroke disability. Thisrepresents the world's first such filing concerning a neural stem cell treatmentfor a major neurological disorder. There are an estimated 50 million strokesurvivors worldwide, approximately one half of which are left with permanentdisabilities. The annual health and social costs of caring for these patientsis estimated to be in excess of £5 billion in the UK and in excess of US$50billion in the US. ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem celltherapy for Huntington's disease, a genetic and fatal neurodegenerative disorderthat affects around 1 in 10,000 people. This programme is in pre-clinicaldevelopment. In addition to its stroke and Huntington's disease programmes,ReNeuron is developing stem cell therapies for Parkinson's disease, Type 1diabetes and diseases of the retina. ReNeuron has also leveraged its stem cell technologies into non-therapeuticareas - its ReNcell(R) range of cell lines for use in research and in drugdiscovery applications in the pharmaceutical industry. ReNeuron's ReNcell(R)CXand ReNcell(R)VM neural cell lines are marketed worldwide under license byMillipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found atwww.reneuron.com. Data sources: UK Stroke Association; American Stroke Association. About Millipore Corporation Millipore is a leading provider of products and services that improveproductivity in biopharmaceutical manufacturing and in clinical, analytical andresearch laboratories. The company is organized in two operating divisions.Its Bioprocess Division helps enables pharmaceutical and biotechnology companiesto optimize their manufacturing productivity, ensure the quality of drugs, andscale up the production of difficult-to-manufacture biologics. Its Biosciencedivision helps to optimize laboratory productivity and workflows. Its productsand enabling technologies that are used in the laboratory are essential for theresearch and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers' research and manufacturingprocess needs, and offers reliable and innovative tools, technologies andservices. The company is part of the S&P 500 index and employs approximately5,800 employees in more than 47 offices worldwide. For additional informationon Millipore Corporation, please visit its website at www.millipore.com. This announcement contains forward-looking statements with respect to thefinancial condition, results of operations and business achievements/performanceof ReNeuron and certain of the plans and objectives of management of ReNeuronwith respect thereto. These statements may generally, but not always, beidentified by the use of words such as "should", "expects", "estimates","believes" or similar expressions. This announcement also containsforward-looking statements attributed to certain third parties relating to theirestimates regarding the growth of markets and demand for products. By theirnature, forward-looking statements involve risk and uncertainty because theyreflect ReNeuron's current expectations and assumptions as to future events andcircumstances that may not prove accurate. A number of factors could causeReNeuron's actual financial condition, results of operations and businessachievements/performance to differ materially from the estimates made or impliedin such forward-looking statements and, accordingly, reliance should not beplaced on such statements. The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement referto ReNeuron Group plc and/or its subsidiary undertakings, depending on thecontext. This information is provided by RNS The company news service from the London Stock Exchange